Pulmonary tuberculosis infection and CMV reactivation following daratumumab treatment in a patient with relapsed plasmablastic lymphoma

作     者：Wenyue Cao Yuling Wan Xingcheng Yang Wei Huang Jia Wei Wenyue Cao;Yuling Wan;Xingcheng Yang;Wei Huang;Jia Wei

作者机构：Department of HematologyTongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina Department of HematologyShanxi Bethune HospitalShanxi Academy of Medical SciencesShanxi Medical UniversityShanxi Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyTaiyuanChina 

出 版 物：《Blood Science》 (血液科学（英文）)

年 卷 期：2022年第4卷第4期

页      面：205-208页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：the fundings from the National Natural Science Foundation of China(81873427 and 82070217 to Dr.Jia Wei) CHEN XIAO-PING Foundation for the Development of Science and Technology of Hubei Province(CXPJJH12000009-113,to Dr.Jia Wei). 

主　　题：CMV Daratumumab Plasmablastic lymphoma Tuberculosis 

摘      要：Plasmablastic lymphoma(PBL)is an aggressive lymphoma with limited treatment strategies.Tuberculosis(TB)infection poses a high risk for patients with hematologic malignancies,especially those treated with immune agents but were never reported postdaratumumab treatment.Herein,we reported a TB infection in a 57-year-old male diagnosed with HIV-negative PBL receiving daratumumab-based treatment,who showed atypical lung infection and yielded Mycobacterium tuberculosis and cytomegalovirus(CMV)in the bronchoalveolar lavage fluid.Anti-TB therapy was administered,and the following daratumumab treatment was complete with good tolerance.In this case,we demonstrated that TB infection might occur after daratumumab therapy,and adequate attention should be paid to atypical symptoms.